Picture courtesy Twitter
Pune: Serum Institute of India (SII) has applied to the Drugs Controller General of India (DCGI) and Union Health ministry for full market authorization of its COVID-19 vaccine Covishield.
Adar Poonawalla, the CEO of SII, tweeted on Friday that the Indian government now has enough data to consider a full market authorization of Oxford-AstraZeneca’s COVID which is produced under the brand name Covishield by the Pune-based firm.
Once the drug regulator and government give the go-ahead, Covishield will be available in medical stores.
Since being approved by DGCI for emergency use in January 2021, Covishield along with Bharat Biotech’s indigenously manufactured Covaxin has been used in India’s massive inoculation programme.
SII, the world’s biggest vaccine maker, has till date supplied over 1.25 billion doses of Covishield, which most Indians have received.
SII currently makes 240 million doses per month and is ready to export ‘large volumes’ from January, Poonawalla told Reuters.
Bhubaneswar: A day before the Pravasi Bharatiya Divas kicks off here, the Global Organization of…
Bhubaneswar: The Capital Region Urban Transport (CRUT) on Tuesday announced launch of two new services…
Hyderabad: Allu Arjun’s ‘Pushpa 2: The Rule’ has broken all box-office records by crossing the…
Dhaka: Bangladesh’s interim government, headed by Nobel Laureate Muhammad Yunus, has revoked the passports of 97…
Dubai: South superstar Ajith Kumar, who is gearing up to participate in the Dubai 24…
New Delhi: Hours after a powerful earthquake jolted Tibet, several aftershocks -- including a 4.1…
This website uses cookies.
